Cell Line

Please note this product may be subject to fees, we invite you to contact your local office.PARP1 Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human PARP1 (Poly-(ADP-ribose) Polymerase 1) has been genetically removed using CRISPR/Cas9 genome editing. This cell line has been validated by genomic sequencing and Western Blot.

Please note this product may be subject to fees, we invite you to contact your local office.PARG Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human PARG (Poly ADP-ribose glycohydrolase) has been genetically removed using CRISPR/Cas9 genome editing. This cell line has been validated by genomic sequencing and Western Blot.

Please note this product may be subject to fees, we invite you to contact your local office.eGFP/Firefly Luciferase BCMA Knockout RPMI 8226 Cell Line is a RPMI 8226 cell Line constitutively expressing firefly (Photinus pyralis) luciferase and the enhanced GFP (eGFP) cassette under the control of a CMV promoter. BCMA (B-Cell Maturation Antigen, or CD269) expression has been genetically removed using CRISPR/Cas9 genome editing. This cell line was generated by using the eGFP/Firefly Luciferase Lentivirus (BPS Bioscience #79980). This cell line has been validated by genome sequencing, flow cytometry and luciferase activity measurement.

Please note this product may be subject to fees, we invite you to contact your local office.Firefly Luciferase BCMA Knockout RPMI-8226 Cell Line is a RPMI-8226 cell Line constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter, and in which BCMA (B-Cell Maturation Antigen, or CD269) has been genetically removed using CRISPR/Cas9 genome editing. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692). This cell line has been validated by genome sequencing, flow cytometry and luciferase activity measurement.

Please note this product may be subject to fees, we invite you to contact your local office.PARP1 Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human PARP1 (Poly-(ADP-ribose) Polymerase 1) has been genetically removed using CRISPR/Cas9 genome editing. This cell line has been validated by genomic sequencing and Western Blot.

Please note this product may be subject to fees, we invite you to contact your local office.PARG Knockout MCF7 Cell Line is an MCF7 breast cancer cell line in which human PARG (Poly ADP-ribose glycohydrolase) has been genetically removed using CRISPR/Cas9 genome editing. This cell line has been validated by genomic sequencing and Western Blot.

The 16HBE140 cell line is derived from human bronchial epithelial cells, which are essential for studying the respiratory epithelium. These cells retain several key characteristics of primary bronchial epithelial cells, including the ability to form tight junctions, express characteristic markers, and exhibit typical epithelial morphology. They are widely used in research focusing on respiratory diseases, drug transport, and toxicology studies, providing a reliable in vitro model to understand bronchial epithelial cell behavior under various conditions. One of the significant applications of 16HBE140 cells is in the investigation of cystic fibrosis (CF), a genetic disorder affecting the respiratory system. These cells express the cystic fibrosis transmembrane conductance regulator (CFTR) protein, making them a valuable tool for studying CF pathophysiology and for screening potential therapeutic agents. Additionally, 16HBE140 cells are utilized in airway inflammation research, given th

The MC38 cell line is a murine model extensively utilized in colorectal carcinoma research. Originating from a colon adenocarcinoma in a C57BL/6 mouse, these cells exhibit a high mutational rate, particularly in the mutanome and neoantigen expression, making them highly sensitive to immune checkpoint inhibitor therapy. Their responsiveness to endogenous CD8+ T cell attacks against neoantigens underscores their value in studying immune interactions within tumor environments, positioning the MC38 model as a pivotal immunoresponsive murine tumor model.

HCC78 is a cell line derived from a primary tumor of a lung adenocarcinoma, specifically a subtype known as mucinous bronchioloalveolar carcinoma. This cell line was established from a male adult patient. HCC78 cells are particularly noted for harboring a unique chromosomal rearrangement involving the ROS1 and SLC34A2 genes, which results in the SLC34A2-ROS1 fusion protein. This fusion protein has been implicated in oncogenic signaling pathways, making HCC78 a valuable model for studying the molecular mechanisms of ROS1 fusion-positive lung cancers and for testing targeted therapies against ROS1.